Segment Information - Schedule of Reportable Segment Net Revenues and Loss (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Revenues:
Type of Revenue [Extensible List]		us-gaap:LicenseMember	us-gaap:LicenseMember
Total revenues		$ 47,977	$ 103,781
Research and development
Research and development expense		96,757	51,440
General and administrative
General and administrative		23,704	25,554
Other segment items	[1]	817	5,320
InvestmentIncomeInterest		(4,735)	(3,937)
Income tax expense		(0)	2,598
Consolidated profit (loss)		(68,566)	22,806
Grant Revenue
Revenues:
Total revenues		20,581	7,046
Collaboration revenue - related party
Revenues:
Total revenues		$ 27,025	$ 95,802
Collaboration revenue
Revenues:
Type of Revenue [Extensible List]		us-gaap:LicenseMember	us-gaap:LicenseMember
Total revenues		$ 371	$ 933
Tebipenem HBr
Research and development
Research and development expense		60,502	16,695
SPR720
Research and development
Research and development expense		16,626	13,031
SPR206
Research and development
Research and development expense		570	3,240
Research and development personnel related (including share-based compensation)
Research and development
Research and development expense		14,111	13,788
Facility related and other, research and development
Research and development
Research and development expense		4,948	4,686
General and administrative
General and administrative		2,318	2,079
General and administrative personnel related (including share-based compensation)
General and administrative
General and administrative		13,188	15,324
Professional and consultant fees
General and administrative
General and administrative		$ 8,198	$ 8,151

[1] Other segment items include restructuring charges (see Note 9), impairment of long-term asset and other income, net.